O'Neill J. Tackling drug-resistant infections globally: final report and recommendations. Government of the United Kingdom. 2016. https://apo.org.au/sites/default/files/resource-files/2016-05/apo-nid63983.pdf. Accessed 20 Apr 2022.

Vázquez-López R, Solano-Gálvez SG, Juárez Vignon-Whaley JJ, Abello Vaamonde JA, Padró Alonzo LA, Rivera Reséndiz A, et al. Acinetobacter baumannii resistance: a real challenge for clinicians. Antibiotics. 2020;9(4):205.

Pogue JM, Zhou Y, Kanakamedala H, Cai B. Burden of illness in carbapenem-resistant Acinetobacter baumannii infections in US hospitals between 2014 and 2019. BMC Infect Dis. 2022;22(1):1–11.

Nguyen M, Joshi SGJJoAM. Carbapenem resistance in Acinetobacter baumannii, and their importance in hospital-acquired infections: a scientific review. J Appl Microbiol. 2021;131(6):2715–38.

Armengol E, Asunción T, Viñas M, Sierra JM. When combined with colistin, an otherwise ineffective rifampicin–linezolid combination becomes active in Escherichia coli, Pseudomonas aeruginosa, and Acinetobacter baumannii. Microorganisms. 2020;8(1):86.

Bai Y, Liu B, Wang T, Cai Y, Liang B, Wang R, et al. In vitro activities of combinations of rifampin with other antimicrobials against multidrug-resistant Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy. 2015;59(3):1466–71.

Lee HJ, Bergen PJ, Bulitta JB, Tsuji B, Forrest A, Nation RL, et al. Synergistic activity of colistin and rifampin combination against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrobial Agents and Chemotherapy. 2013;57(8):3738–45.

Nordqvist H, Nilsson LE, Claesson C. Mutant prevention concentration of colistin alone and in combination with rifampicin for multidrug-resistant Acinetobacter baumannii. Eur J Clin Microbiol Infect Dis. 2016;35(11):1845–50.

Oh S, Chau R, Nguyen AT, Lenhard JR. Losing the battle but winning the war: Can defeated antibacterials form alliances to combat drug-resistant pathogens? Antibiotics. 2021;10(6):646.

Park HJ, Cho JH, Kim HJ, Han SH, Jeong SH, Byun MK. Colistin monotherapy versus colistin/rifampicin combination therapy in pneumonia caused by colistin-resistant Acinetobacter baumannii: A randomised controlled trial. J Glob Antimicrob Resist. 2019;17:66–71.

Scudeller L, Righi E, Chiamenti M, Bragantini D, Menchinelli G, Cattaneo P, et al. Systematic review and meta-analysis of in vitro efficacy of antibiotic combination therapy against carbapenem-resistant Gram-negative bacilli. Int J Antimicrob Agents. 2021;57(5):106344.

Petrosillo N, Ioannidou E, Falagas ME. Colistin monotherapy vs. combination therapy: evidence from microbiological, animal and clinical studies. Clin Microbiol Infect. 2008;14(9):816–27.

Tuon FF, Rocha JL, Merlini AB. Combined therapy for multi-drug-resistant Acinetobacter baumannii infection–is there evidence outside the laboratory? J Med Microbiol. 2015;64(9):951–9.

Durante-Mangoni E, Signoriello G, Andini R, Mattei A, De Cristoforo M, Murino P, et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis. 2013;57(3):349–58.

Goutelle S, Bourguignon L, Maire PH, Van Guilder M, Conte Jr JE, Jelliffe RW. Population modeling and Monte Carlo simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of rifampin in lungs. Antimicrob Agents Chemother. 2009;53(7):2974–81.

Gumbo T, Louie A, Deziel MR, Liu W, Parsons LM, Salfinger M, Drusano GL. Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob Agents Chemother. 2007;51(11):3781–8.

Lepe JA, García-Cabrera E, Gil-Navarro MV, Aznar JJ. Rifampin breakpoint for Acinetobacter baumannii based on pharmacokinetic-pharmacodynamic models with Monte Carlo simulation. Revista Española de Quimioterapia. 2012;25(2).

Rolain JM, Diene SM, Kempf M, Gimenez G, Robert C, Raoult D. Real-time sequencing to decipher the molecular mechanism of resistance of a clinical pan-drug-resistant Acinetobacter baumannii isolate from Marseille, France.Antimicrob Agents Chemother. 2013;57(1):592–6.

Jayaram R, Gaonkar S, Kaur P, Suresh B, Mahesh B, Jayashree R, et al. Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother. 2003;47(7):2118–24.

Regoes RR, Wiuff C, Zappala RM, Garner KN, Baquero F, Levin BR. Pharmacodynamic functions: a multiparameter approach to the design of antibiotic treatment regimens. Antimicrob Agents Chemother. 2004;48(10):3670–6.

Ramachandran G, Chandrasekaran P, Gaikwad S, Agibothu Kupparam HK, Thiruvengadam K, Gupte N, et al. Subtherapeutic rifampicin concentration is associated with unfavorable tuberculosis treatment outcomes. Clin Infect Dis. 2020;70(7):1463–70.

Perea-Jacobo R, Muñiz-Salazar R, Laniado-Laborín R, Cabello-Pasini A, Zenteno-Cuevas R, Ochoa-Terán A. Rifampin pharmacokinetics in tuberculosis-diabetes mellitus patients: a pilot study from Baja California, Mexico. The International Journal of Tuberculosis and Lung Disease. 2019;23(9):1012–6.

Loubinoux J, Mihaila-Amrouche L, Le Fleche A, Pigne E, Huchon G, Grimont PAD, et al. Bacteremia caused by Acinetobacter ursingii. J Clin Microbiol. 2003;41(3):1337–8.

Article  Google Scholar 

Bassetti M, Repetto E, Righi E, Boni S, Diverio M, Molinari MP, et al. Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections. J Antimicrob Chemother. 2008;61(2):417–20.

CAS  Article  Google Scholar 

Motaouakkil S, Charra B, Hachimi A, Nejmi H, Benslama A, Elmdaghri N, et al. Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii. J Infect. 2006;53(4):274–8.

Article  Google Scholar 

Svensson RJ, Aarnoutse RE, Diacon AH, Dawson R, Gillespie SH, Boeree MJ, Simonsson US. A population pharmacokinetic model incorporating saturable pharmacokinetics and autoinduction for high rifampicin doses. Clinical Pharmacology & Therapeutics. 2018;103(4):674–83.

Cresswell FV, Meya DB, Kagimu E, Grint D, te Brake L, Kasibante J, et al. High-Dose Oral and Intravenous Rifampicin for the Treatment of Tuberculous Meningitis in Predominantly Human Immunodeficiency Virus (HIV)-Positive Ugandan Adults: A Phase II Open-Label Randomized Controlled Trial. Clin Infect Dis. 2021;73(5):876–84.

CAS  Article  Google Scholar 

Ruiz-Bedoya CA, Mota F, Tucker EW, Mahmud FJ, Reyes-Mantilla MI, Erice C, et al. High-dose rifampin improves bactericidal activity without increased intracerebral inflammation in animal models of tuberculous meningitis. J Clin Investig. 2022;132(6).

Garcia-Prats AJ, Svensson EM, Winckler J, Draper HR, Fairlie L, van der Laan LE, et al. Pharmacokinetics and safety of high-dose rifampicin in children with TB: the Opti-Rif trial. 2021;76.46-3237:(12).

Seijger C, Hoefsloot W, Bergsma-de Guchteneire I, te Brake L, van Ingen J, Kuipers S, et al. High-dose rifampicin in tuberculosis: Experiences from a Dutch tuberculosis centre. PLoS ONE. 2019;14(3):e0213718.

CAS  Article  Google Scholar 

Zhu LL, Zhou Q. Therapeutic concerns when oral medications are administered nasogastrically. J Clin Pharm Ther. 2013;38(4):272–6.

Lindahl A, Ungell AL, Knutson L, Lennernäs H. Characterization of fluids from the stomach and proximal jejunum in men and women. Pharm Res. 1997;14(4):497–502.

Cheng L, Wong H. Food effects on oral drug absorption: application of physiologically-based pharmacokinetic modeling as a predictive tool. Pharmaceutics. 2020;12(7):672.

Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268–81.

CAS  Article  Google Scholar 

Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, Kumar A, Sevransky JE, Sprung CL, Nunnally ME, Rochwerg B. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 2017;43(3):304–77.

Albers I, Hartmann H, Bircher J, Creutzfeldt W. Superiority of the Child-Pugh classification to quantitative liver function tests for assessing prognosis of liver cirrhosis. Scand J Gastroenterol. 1989;24(3):269–76.

Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41.

CAS  Article  Google Scholar 

Kim YC, Park JY, Kim B, Kim ES, Ga H, Myung R, et al. Prescriptions patterns and appropriateness of usage of antibiotics in non-teaching community hospitals in South Korea: a multicentre retrospective study. Antimicrob Resist Infect Control. 2022;11(1):1–13.

Baniasadi S, Shahsavari N, Namdar R, Kobarfard F. Stability assessment of isoniazid and rifampin liquid dosage forms in a national referral center for tuberculosis. Int J Pharm Sci Res. 2015;6(4):706–9.

Nahata MC, Morosco RS, Hippie TF. Stability of rifampin in two suspensions at room temperature. J Clin Pharm Ther. 1994;19(4):263–5.

CAS  Article  Google Scholar 

Ruslami R, Nijland HM, Alisjahbana B, Parwati I, van Crevel R, Aarnoutse RE. Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients. Antimicrob Agents Chemother. 2007;51(7):2546–51.

Cochran WG. Sampling techniques. John Wiley & Sons. 1977.

Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. The AAPS journal. 2011;13(2):143–51.

Kiang TK, Sherwin CM, Spigarelli MG, Ensom MH. Fundamentals of population pharmacokinetic modelling. Clin Pharmacokinet. 2012;51(8):515–25.

Wasserman S, Davis A, Stek C, Chirehwa M, Botha S, Daroowala R, et al. Plasma pharmacokinetics of high-dose oral versus intravenous Rifampicin in patients with tuberculous Meningitis: a randomized controlled trial. Antimicrob Agents Chemother. 2021;65(8):e00140–21.

Rao PS, Moore CC, Mbonde AA, Nuwagira E, Orikiriza P, Nyehangane D, et al. Population pharmacokinetics and significant under-dosing of anti-tuberculosis medications in people with HIV and critical illness. Antibiotics. 2021;10(6):739.

Te Brake LH, de Jager V, Narunsky K, Vanker N, Svensson EM, Phillips PP, et al. Increased bactericidal activity but dose-limiting intolerability at 50 mg·kg−1 rifampicin. Eur Respir J. 2021;58.(1).

Omachi F, Kaneko M, Iijima R, Watanabe M, Itagaki F. Relationship between the effects of food on the pharmacokinetics of oral antineoplastic drugs and their physicochemical properties. J Pharm Health Care Sci. 2019;5(1):26.

Article  Google Scholar 

Acocella G. Clinical pharmacokinetics of rifampicin. Clin Pharmacokinet. 1978;3(2):108–27.

Furesz S, Scotti R, Pallanza R, Mapelli E. Rifampicin: a new rifamycin. 3. Absorption, distribution, and elimination in man. Arzneimittel-Forschung. 1967;17(5):534–7.

Zent C, Smith P. Study of the effect of concomitant food on the bioavailability of rifampicin, isoniazid and pyrazinamide. Tubercle Lung Dis. 1995;76(2):109–13.

CAS  Article  Google Scholar 

Kumar AKH, Chandrasekaran V, Kumar AK, Kawaskar M, Lavanya J, Swaminathan S, et al. Food significantly reduces plasma concentrations of first-line anti-tuberculosis drugs. Indian J Med Res. 2017;145(4):530–5.

CAS  PubMed  PubMed Central  Google Scholar 

Saktiawati AMI, Sturkenboom MGG, Stienstra Y, Subronto YW, Sumardi, Kosterink JGW, et al. Impact of food on the pharmacokinetics of first-line anti-TB drugs in treatment-naive TB patients: a randomized cross-over trial. J Antimicrob Chemother. 2015;71(3):703–10.

Van Scoy RE, Wilkowske CJ. Antituberculous Agents. Mayo Clin Proc. 1992;67(2):179–87.

Article  Google Scholar 

Verbist L, Gyselen A. Antituberculous activity of rifampin in vitro and in vivo and the concentrations attained in human blood. Am Rev Respir Dis. 1968;98(6):923–32.

CAS  PubMed  Google Scholar 

Peloquin CA, Namdar R, Singleton MD, Nix DE. Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids. Chest. 1999;115(1):8–12.

Article  Google Scholar 

Haussner F, Chakraborty S, Halbgebauer R, Huber-Lang M. Challenge to the Intestinal Mucosa During Sepsis. Front Immunol. 2019;10:891.

CAS  Article  Google Scholar 

Yan Y, Chen Y, Zhang X. The effect of opioids on gastrointestinal function in the ICU. Critical Care. 2021;25(1):1–14.

Kenny MT, Strates B. Metabolism and pharmacokinetics of the antibiotic rifampin. Drug Metab Rev. 1981;12(1):159–218.

CAS  Article  Google Scholar 

Nijland HMJ, Ruslami R, Stalenhoef JE, Nelwan EJ, Alisjahbana B, Nelwan RHH, et al. Exposure to Rifampicin Is Strongly Reduced in Patients with Tuberculosis and Type 2 Diabetes. Clin Infect Dis. 2006;43(7):848–54.

CAS  Article  Google Scholar 

Yeo CJ, Couse NF, Antiohos C, Zinner MJ. The effect of norepinephrine on intestinal transport and perfusion pressure in the isolated perfused rabbit ileum. J Surg Res. 1988;44(5):617–24.

CAS  Article  Google Scholar 

Feng X-Q, Zhu L-L, Zhou Q. Opioid analgesics-related pharmacokinetic drug interactions: from the perspectives of evidence based on randomized controlled trials and clinical risk management. J Pain Res. 2017;10:1225–39.

CAS  Article  Google Scholar 

Mummaneni V, Amidon GL, Dressman JB. Gastric pH influences the appearance of double peaks in the plasma concentration-time profiles of cimetidine after oral administration in dogs. Pharm Res. 1995;12(5):780–6.

Godfrey KR, Arundel PA, Dong Z, Bryant R. Modelling the double peak phenomenon in pharmacokinetics. Computer Methods and Programs in Biomedicine. 2011;104(2):62–9.

Krause A, Lavielle M, Chatel K, Kohl C, de Kanter R, de la Haye S, et al. Modeling the two peak phenomenon in pharmacokinetics using a gut passage model with two absorption sites. 2013. Available at: https://www.page-meeting.org/default.asp?abstract=2779. Accessed 12 Apr 2022.

Wang Y, Roy A, Sun L, Lau CE. A double-peak phenomenon in the pharmacokinetics of alprazolam after oral administration. Drug Metabolism and Disposition. 1999;27(8):855–9.

Gerner B, Scherf-Clavel O. Physiologically based pharmacokinetic modelling of cabozantinib to simulate enterohepatic recirculation, drug–drug interaction with rifampin and liver impairment. Pharmaceutics. 2021;13(6):778.

Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, Machado FR, Mcintyre L, Ostermann M, Prescott HC, Schorr C. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med. 2021;47(11):1181–247.

Shahrami B, Sharif M, Sefidani Forough A, Najmeddin F, Arabzadeh AA, Mojtahedzadeh M. Antibiotic therapy in sepsis: No next time for a second chance! J Clin Pharm Ther. 2021;46(4):872–6.

Article  Google Scholar 

Karakonstantis S, Ioannou P, Samonis G, Kofteridis DP. Systematic review of antimicrobial combination options for pandrug-resistant Acinetobacter baumannii. Antibiotics. 2021;10(11):1344.

Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America Guidance on the Treatment of AmpC β-Lactamase–Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections. Clin Infect Dis. 2022;74(12):2089–114.

Bai Y, Liu B, Wang T, Cai Y, Liang B, Wang R, et al. In Vitro activities of combinations of rifampin with other antimicrobials against multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2015;59(3):1466–71.

Article  Google Scholar 

Lee HJ, Bergen PJ, Bulitta JB, Tsuji B, Forrest A, Nation RL, et al. Synergistic activity of colistin and rifampin combination against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother. 2013;57(8):3738–45.

CAS  Article  Google Scholar 

Aydemir H, Akduman D, Piskin N, Comert F, Horuz E, Terzi A, Kokturk F, Ornek T, Celebi G. Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia. Epidemiol Infect. 2013;141(6):1214–22.

Koegelenberg CF, Nortje A, Lalla U, Enslin A, Irusen EM, Rosenkranz B, Seifart HI, Bolliger CT. The pharmacokinetics of enteral antituberculosis drugs in patients requiring intensive care. S Afr Med J. 2013;103(6):394–8.

Imberti R, Cusato M, Villani P, Carnevale L, Iotti GA, Langer M, Regazzi M. Steady-state pharmacokinetics and BAL concentration of colistin in critically Ill patients after IV colistin methanesulfonate administration. Chest. 2010;138(6):1333–9.

Cheah SE, Wang J, Nguyen VT, Turnidge JD, Li J, Nation RL. New pharmacokinetic/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse thigh and lung infection models: smaller response in lung infection. J Antimicrob Chemother. 2015;70(12):3291–7.

Tsuji BT, Pogue JM, Zavascki AP, Paul M, Daikos GL, Forrest A, Giacobbe DR, Viscoli C, Giamarellou H, Karaiskos I, Kaye D. International consensus guidelines for the optimal use of the polymyxins: endorsed by the American college of clinical pharmacy (ACCP), European society of clinical microbiology and infectious diseases (ESCMID), infectious diseases society of America (IDSA), international society for anti‐infective pharmacology (ISAP), society of critical care medicine (SCCM), and society of infectious diseases pharmacists (SIDP). Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2019;39(1):10–39.

Varshochi M, Hasani A, Derakhshanfar SJ, Bayatmakoo Z, Ghavghani FR, Poorshahverdi P, et al. In vitro susceptibility testing of Rifampin against Acinetobacter Baumannii: Comparison of disk diffusion, agar dilution, and e-test. Erciyes Medical Journal. 2019;41(4):364–9.